Janssen Search
Search results
How Surprising New Research Is Tapping the Powers of the Immune System
Article Block Text: Article Type: Research and Innovation Immunology How Surprising New Research Is Tapping the Powers of the Immune System Your immune system does so much more than simply fight off colds. In recognition of National Autoimmune Disease ...
RYBREVANT® (amivantamab-vmjw) plus lazertinib is the only chemotherapy-free regimen showing longer progression-free survival versus osimertinib in first-line treatment of patients with high-risk EGFR-mutated non-small cell lung cancer
May 31, 2024 Investigational chemotherapy-free regimen of RYBREVANT® plus lazertinib addresses a significant unmet need as most patients with EGFR-mutated NSCLC have high-risk disease Landmark Phase 3 MARIPOSA data featured in an oral presentation at ASCO ...
Late-breaking results from PALOMA-2 study of subcutaneous amivantamab in combination with lazertinib show clinically meaningful antitumor response and improved safety profile in patients with EGFR-mutated non-small cell lung cancer
Jun 03, 2024 Significantly lower infusion-related reactions seen with subcutaneous amivantamab compared with intravenous administration in new Phase 2 data CHICAGO (June 3, 2024) – Johnson & Johnson announced today new data from the Phase 2 PALOMA-2 ...
Subcutaneous amivantamab Biologics License Application submitted to U.S. FDA for patients with EGFR-mutated non-small cell lung cancer
Jun 17, 2024 Application based on Phase 3 PALOMA-3 results showing five-fold reduction in infusion-related reactions with five-minute administration of subcutaneous amivantamab Longer overall survival, progression-free survival and duration of response ...
Johnson & Johnson showcases innovation and leadership in rheumatology at EULAR 2024 Congress
Jun 07, 2024 30 abstracts highlight the company’s robust portfolio and commitment to improving outcomes for patients with immune-mediated diseases Features positive results from a Phase 2 study of nipocalimab in Sjögren’s disease as a late-breaking oral ...
CARVYKTI® (ciltacabtagene autoleucel) achieved statistically significant and clinically meaningful improvement in overall survival in landmark CARTITUDE-4 study
Jul 02, 2024 CARVYKTI ® is the first and only BCMA-targeted CAR-T cell therapy approved by the U.S. FDA for the treatment of patients with multiple myeloma who have had at least one prior line of therapy RARITAN, N.J., (July 2, 2024) /PRNewswire/ – ...
New Analyses Demonstrate Versatility and Continued Efficacy of TALVEY™ in the Treatment of Patients with Relapsed or Refractory Multiple Myeloma
Dec 11, 2023 United States Analysis from MonumenTAL-1 study showed patients with relapsed or refractory multiple myeloma treated with TALVEY™ were subsequently treated effectively with several classes of therapy, including CAR-T Additional presentations ...
This Is Your Brain with Schizophrenia: How the Illness Manifests and What Researchers Are Doing to Help
This Is Your Brain with Schizophrenia: How the Illness Manifests and What Researchers Are Doing to Help Article Type: Research and Innovation Neuroscience Even if you don’t know anyone who has schizophrenia, chances are you’re familiar with the symptoms. ...
Will Ebola Continue to Re-Emerge?
Will Ebola Continue to Re-Emerge? In this post, Janssen’s Dr. Allitia Di Bernardo looks at how Janssen is fighting to prevent Ebola outbreaks before they begin. Since stepping into my role as Europe, Middle East & Asia (EMEA) Therapeutic Area Lead ...
DARZALEX® (daratumumab)-based regimens significantly improve clinical outcomes in both transplant-eligible and-ineligible patients who are newly diagnosed with multiple myeloma
Jun 03, 2024 88 percent of transplant-eligible patients achieved a complete response or better, and 47 percent of patients sustained MRD-negativity for longer than one year with DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj)-based induction, ...